Down syndrome and type I interferon: not so simple.

Area of Science:

• Genetics
• Immunology
• Developmental Biology

Background:

• Down syndrome (DS) presents with intellectual disability, congenital malformations, and immune dysregulation.
• The genetic basis for specific DS clinical features remains incompletely understood.
• Type I interferons (IFN-I) are crucial cytokines involved in antiviral and inflammatory responses.

Purpose of the Study:

• To review the literature on the role of IFN-I in Down syndrome pathogenesis.
• To compare and contrast DS with other IFN-mediated human diseases.
• To identify potential therapeutic targets within the IFN-I pathway for DS.

Main Methods:

• Literature review of studies on Down syndrome and IFN-I.
• Comparative analysis of clinical and molecular features of DS and IFN-mediated monogenic diseases.
• Identification of testable hypotheses for DS mechanisms.

Main Results:

• Genes IFNAR1 and IFNAR2, encoding the IFN-I receptor subunits on chromosome 21, are implicated in DS pathogenesis.
• Human monogenic diseases of IFN-I dysregulation share clinical overlap with DS but exhibit distinct features.
• The IFN-I system represents a significant factor in DS pathophysiology.

Conclusions:

• The IFN-I pathway is a key area for understanding Down syndrome.
• IFN-I dysregulation contributes to DS clinical manifestations.
• Further research into IFN-I in DS may reveal novel therapeutic strategies.